Date	Event	Description
4 October 2018	New citation required but conclusions have not changed	Updating this review did not change the conclusion of the previous version of this review that antiplatelet agents reduce pre‐eclampsia, preterm birth, and neonatal death.
4 October 2018	New search has been performed	Search updated. Updated previously included studies with available individual participant data (IPD), added IPD from two not previously included studies (Pergar 1987; Spain 2003), and added aggregate data (AD) from 17 new studies (Algeria 2011; ASPRE 2017; Brazil 2006; Canada 2017, Finland 2013; Germany 1995; India 1991; India 2017Iran 1992; Iran 2006; Iran 2010; Iran 2012; Iran 2014a, Korea 1997; Netherlands 2009, Romania 2018, Spain 2017). The use of IPD enabled us to classify participants by risk of developing pre‐eclampsia and analyse the effect of antiplatelet agents for different risk groups. Including the new studies and IPD in the updated review allowed for the novel inclusion of the two key outcomes, postpartum haemorrhage and pregnancy with serious adverse outcome (composite including maternal death, baby death, pre‐eclampsia, small‐for‐gestational age, preterm birth). Antiplatelet agents reduced the risk of pregnancy with serious adverse outcome, but probably slightly increased the risk of postpartum haemorrhage (> 500 mL). A prepublication search in September identified 27 new trial reports. These have been added to the Studies awaiting classification section for consideration at the next update.